Ignite Creation Date:
2024-05-05 @ 5:09 PM
Last Modification Date:
2024-10-26 @ 9:28 AM
Study NCT ID:
NCT00396786
Status:
COMPLETED
Last Update Posted:
2014-10-28
First Post:
2006-11-06
Brief Title:
Dose-ranging Study of Once-daily Regimen of BAY 59-7939 in the Prevention of VTE in Patients Undergoing Elective Total Hip Replacement
Sponsor:
Bayer
Organization:
Bayer
Study Overview
Official Title:
Controlled Double-Blind Randomized Dose-ranging Study of Once-daily Regimen of BAY59-7939 in the Prevention of VTE in Patients Undergoing Elective Total Hip Replacement- ODIXaHIP-OD
Status:
COMPLETED
Status Verified Date:
2014-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ODIXaHIP-OD
Brief Summary:
The purpose of this study is to assess different doses of a new drug BAY 59-7939 taken as a tablet are safe and can help prevent blood clots forming after a hip replacement operation Patients undergoing hip replacement surgery are at risk of developing blood clots To reduce this risk treatment to prevent clots forming is routinely given The current treatments can include injections under the skin or other treatments that need frequent blood tests to monitor levels of drug in the body Therefore there is a need for new drugs which are easier to give and need less monitoring
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| EudraCT No 2004-001341-14 | None | None | None |